Comparative Pharmacology
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus TIMOLOL MALEATE.
BETAXOLOL HYDROCHLORIDE vs TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Non-selective beta-adrenergic receptor antagonist (beta-blocker). Competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and cardiac output. Also decreases aqueous humor production in the eye by blocking beta2 receptors on ciliary epithelium.
10-20 mg orally once daily; maximum 20 mg/day.
Systemic: 1 drop of 0.25% or 0.5% solution in affected eye(s) twice daily. Additional indication: 0.5% gel-forming solution once daily. Oral: 10 mg twice daily, may increase to 20 mg twice daily if needed.
None Documented
None Documented
Terminal elimination half-life: 14–22 hours (mean 16 hours); sufficient for once-daily dosing in hypertension; prolonged in renal impairment.
2-3 hours (terminal); prolonged in hepatic impairment
Renal: 80% (as unchanged drug and inactive metabolites), Fecal: 20%
Renal: 20% unchanged; biliary/fecal: 80% as metabolites
Category C
Category A/B
Beta-Blocker
Beta-Blocker